STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more

Revolution Medicines' pancreatic cancer drug daraxonrasib showed a 60% reduction in mortality risk compared to chemotherapy, with a median survival of 13.2 months. China's biotechnology sector is rapidly growing, marked by a first-ever China-only clinical trial presentation at the ASCO conference.